Oxalo Therapeutics

About:

Oxalo Therapeutics creates drugs to treat rare kidney diseases and prevent recurring kidney stones.

Website: https://www.oxalotherapeutics.com/

Top Investors: National Science Foundation, National Institutes of Health, MassChallenge, Polsky Center at the University of Chicago

Description:

Oxalo Therapeutics creates drugs to treat rare kidney diseases and prevent recurring kidney stones. Oxalo Therapeutics is tackling primary hyperoxaluria and other oxalate pathologies. Oxalo Therapeutics develops innovative therapies by leveraging its expertise in the microbiome, translational research, and early-stage technology commercialization. Oxalo's method mimics a natural mechanism for safely removing oxalate from the body, thereby preventing recurrent kidney stones and other oxalate pathologies.

Total Funding Amount:

$3.77M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chicago, Illinois, United States

Founded Date:

2017-01-01

Founders:

Hatim Hassan, Yang Zheng

Number of Employees:

1-10

Last Funding Date:

2022-04-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai